Source: Eur Respir J 2014; 44: 1156-1165
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Jones Paul W., Lamarca Rosa, Chuecos Ferran, Singh Dave, Agustí Alvar, Bateman Eric D., de Miquel Gonzalo, Caracta Cynthia, Garcia Gil Esther. Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. Eur Respir J 2014; 44: 1156-1165

Member's Comments

No comment yet.

Related content which might interest you: Characteristics of COPD patients with repeated exacerbations: preliminary results from the PRE-SPIRO survey Source: Annual Congress 2008 - COPD epidemiology Year: 2008 Persistence to COPD therapies and impact on exacerbations: a French claims data study Source: International Congress 2018 – Respiratory epidemiology: from COPD to factors that associate with lung function and infections Year: 2018 Preliminary results of relationship between appetite and clinical presentation of COPD patients in AERIS study Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD Year: 2015 Acute exacerbation phenotypes of asthma and COPD: impact on clinical outcomes Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations Year: 2021 The long-term clinical and economic impact of COPD exacerbations: an observational study (SHERLOCK) Source: Virtual Congress 2020 – Prediction and management of outcomes in obstructive diseases Year: 2020 Efficacy of roflumilast in patients with a history of frequent exacerbations: Pooled data from pivotal 12-month studies Source: Annual Congress 2010 - COPD: management Year: 2010 LATE-BREAKING ABSTRACT: Large differences in rate of reported and unreported COPD exacerbations in Japanese patients; data from the COSMOS-J trial Source: International Congress 2016 – Clinical characteristics of asthma Year: 2016 Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Prediction models for exacerbations in different COPD patient populations: Results of five large databases Source: International Congress 2016 – COPD and asthma COPD overlap syndrome (ACOS): novelties in terms of prevalence, risk factors, and prognosis in COPD Year: 2016 Prediction of exacerbations (EXAC) by evaluation of patient characteristics and previous events in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 90s Year: 2004 Impact of patients’ setting on the prevalence of pulmonary embolism in acute exacerbation of COPD : a meta-analysis of observational studies. Source: International Congress 2017 – Pulmonary embolism Year: 2017 Sit-to-stand ability in patients hospitalised for acute exacerbation of COPD: Clinical characteristics and short-term outcomes Source: International Congress 2015 – New insights into exercise and muscle performance Year: 2015 Real-world exacerbation rates in Japanese patients with COPD: results from the EXACOS observational cohort study Source: Virtual Congress 2021 – Biomarkers to phenotype COPD: prediction of exacerbations Year: 2021 Identifying factors associated with severe asthma exacerbations: a retrospective study Source: Eur Respir J 2007; 30: Suppl. 51, 626s Year: 2007 COPD exacerbations: impact and prevention Source: Breathe 2013; 9: 434-440 Year: 2013 Modelling and simulation in successful drug development programmes: Characterisation of exacerbation reduction with roflumilast to corroborate the importance of defining patient subsets in COPD Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Agreement between patient-reported and chart documented outcomes: Case study in COPD Source: Annual Congress 2013 –Lung function tests to monitor airway diseases Year: 2013 Factors affecting survival after severe COPD exacerbations: a single-center experience. Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020 Dupilumab reduces severe exacerbation-related costs among asthma patients: Results from a phase 2b trial Source: International Congress 2016 – How the increasing complexity of chronic care management challenges ethics and costs in our healthcare system Year: 2016 Patterns, predictors and outcomes of asthma control and exacerbations during pregnancy: a prospective cohort study Source: ERJ Open Res 2016 Year: 2016